Title: Randomized, Phase II, Placebo-Controlled, Double-Blind Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin As First-Line Treatment Followed by Maintenance Treatment in Advanced Ovarian Cancer
Authors: Vergote, Ignace ×
Chekerov, Radoslav
Amant, Frédéric
Harter, Philipp
Casado, Antonio
Emerich, Janusz
Bauknecht, Thomas
Mansouri, Kambiz
Myrand, Scott P
Nguyen, Tuan S
Shi, Peipei
Sehouli, Jalid #
Issue Date: Sep-2013
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:31 issue:25 pages:3127-32
Abstract: Enzastaurin is an oral serine/threonine kinase inhibitor antitumor agent. Our phase II trial tested the efficacy and safety of enzastaurin added to a standard carboplatin/paclitaxel chemotherapy regimen in patients with newly diagnosed advanced ovarian cancer.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science